Compare CSAN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSAN | ICUI |
|---|---|---|
| Founded | 1936 | 1984 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | 2008 | 1995 |
| Metric | CSAN | ICUI |
|---|---|---|
| Price | $3.00 | $157.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.75 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 995.8K | 269.5K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $321.51 | N/A |
| Revenue Next Year | $3.57 | $4.46 |
| P/E Ratio | ★ N/A | $127.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.52 | $107.02 |
| 52 Week High | $6.01 | $162.85 |
| Indicator | CSAN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 58.75 |
| Support Level | $2.71 | $139.88 |
| Resistance Level | $3.19 | $161.30 |
| Average True Range (ATR) | 0.09 | 4.89 |
| MACD | 0.02 | -0.64 |
| Stochastic Oscillator | 31.38 | 66.11 |
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.